Potential protective effect of sunitinib after administration of diclofenac: Biochemical and histopathological drug-drug interaction assessment in a mouse model

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 7, 2013, Pages 619-633

  Tan, Jian Ren ^a   Chakravarthi, Srikumar ^a   Judson, John Paul ^a   Haleagrahara, Nagaraja ^a,b   Segarra, Ignacio ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b JAMES COOK UNIVERSITY   (Australia)

Author keywords

Biomarker; Diclofenac; Hepatoprotective effect; Histopathology; Sunitinib

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; DICLOFENAC; SODIUM CHLORIDE; SUNITINIB; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHONDROPROTECTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; HISTOPATHOLOGY; KIDNEY FUNCTION; LIVER FUNCTION; MALE; MOUSE; NONHUMAN; UREA BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ALANINE TRANSAMINASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ASPARTATE AMINOTRANSFERASES; BLOOD UREA NITROGEN; BRAIN; CREATININE; DICLOFENAC; DRUG INTERACTIONS; DRUG-INDUCED LIVER INJURY; INDOLES; KIDNEY; LIVER; MALE; MICE; MICE, INBRED ICR; MYOCARDIUM; PROTECTIVE AGENTS; PROTEIN KINASE INHIBITORS; PYRROLES; SPLEEN;

EID: 84879081872     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-013-0861-4     Document Type: Article

References (62)

1. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478
2. Armour A, Slater SD (1993) Paracetamol cardiotoxicity. Postgrad Med J 69:52-54. doi: 10.1136/pgmj.69.807.52
3. Bello C, Houk B, Sherman L, Misbah S, Sarapa N, Smeraglia J, Haung X (2005) Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers. J Clin Oncol 23(16S):3078
4. Bello CL, Sherman L, Zhou J, Verkh L, Smeraglia J, Mount J, Klamerus KJ (2006) Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anti-Cancer Drugs 17:353-358. doi: 10.1097/00001813- 200603000-00015
5. Boelsterli U (2003) Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol App Pharmacol 192:307-322. doi: 10.1016/S0041-008X(03)00368-5
6. Bowlin SJ, Xia F, Wang W, Robinson KD, Stanek EJ (2013) Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents. Mayo Clin Proc 88:139-148. doi: 10.1016/j.mayocp.2012.10.020
7. Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, Slamon D (2008) A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemoth Pharmacol 61:515-524
8. Chen MH, Kerkela R, Force T (2008) Mechanisms of cardiomyopathy associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 118:84-95. doi: 10.1161/CIRCULATIONAHA.108.776831
9. Chow LQM, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25:884-896. doi: 10.1200/JCO.2006.06.3602
10. Christo PJ, Mazloomdoost D (2008) Cancer pain and analgesia. Ann NY Acad Sci 1138:278-298. doi: 10.1196/annals.1414.033
11. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011-2019. doi: 10.1016/S0140-6736(07)61865-0
12. Chuasuwan B, Binjesoh V, Polli JE, Zhange H, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM (2009) Biowaiver monographs for immediate release solid oral dosage forms: diclofenac sodium and diclofenac potassium. J Pharm Sci 98:1206-1215. doi: 10.1002/jps.21525
13. Eisenberg E, Berkey CS, Carr DB, Mosteller F, Chalmers TC (1994) Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 12:2756-2765
14. Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JVS, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R (2007) Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13:1367-1373. doi: 10.1158/1078-0432.CCR-06-2328
15. Gu J, Cui H, Behr M, Zhabg QY, Yang W, Hinson JA, Ding X (2005) In vivo mechanisms of tissue-selective drug toxicity: effect of liver-specific knockout of the NADPH-cytochrome P450 reductase gene on acetaminophen toxicity in kidney, lung and nasal mucosa. Mol Pharmacol 67:623-630. doi: 10.1124/mol.104.007898
16. Haznedar J, Patyna S, Bello CL, Peng G, Speed W, Yu XM, Zhang QL, Skubuntherng J, Sweeny D, Antonian L, Wu E (2008) Single and multiple dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol 64:691-706. doi: 10.1007/s00280-008-0917-1
17. Hiles JJ, Kolesar JM (2008) Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health-Syst Pharm 65:123-131. doi: 10.2146/ajhp060661
18. Hinson JA, Roberts DW, James LP (2012) Mechanisms of acetaminophen induced liver necrosis. Handb Exp Pharmacol 196:369-405. doi: 10.1007/978-3-642-00663-0-12
19. Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD (2009) Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 15:6062-6069. doi: 10.1158/1078-0432.CCR-09-0048
20. Huang H, Lai JY, Do J, Liu D, Li L, Del Rosario J, Doppalapudi VR, Pirie-Shepherd S, Levin N, Bradshaw C, Woodnutt G, Lappe R, Bhat A (2011) Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res 17:1001-1011. doi: 10.1158/1078-0432.CCR-10-2317
21. Ilic S, Drmic D, Franjic S, Kolenc D, Coric M, Brcic L, Klicek R, Radic B, Sever M, Djuzel V, Filipovic M, Djakovic Z, Stambolija V, Blagaic AB, Zoricic I, Gjurasin M, Stupnisek M, Romic Z, Zarkovic K, Dzidic S, Seiwerth S, Sikiric P (2011) Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions. Life Sci 88:535-542. doi: 10.1016/j.lfs.2011.01.015
22. Jhaveri KD, Flombaum CD, Kroog G, Glezerman IG (2011) Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature. Nephron Clin Pract 117:312-319. doi: 10.1159/000319885
23. Lacouture ME, Reilly LM, Gerami P, Guitart J (2008) Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 19:1955-1961. doi: 10.1093/annonc/mdn389
24. Lagas JS, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH (2010) Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters. Mol Pharmacol 77:687-694. doi: 10.1124/mol.109.062364
25. Li H, Hortmann M, Daiber A, Oelze M, Ostad MA, Schwarz PM, Xu H, Xia N, Kleschyov AL, Mang C, Warnholtz A, Münzel T, Förstermann U (2008) Cyclooxygenase 2-selective and nonselective nonsteroideal anti-inflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidases. J Pharmacol Exp Ther 326:745-753. doi: 10.1124/jpet.108.139030
26. Lim AYL, Segarra I, Chakravarthi S, Akram S, Judson JP (2010) Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice. BMC Pharmacol 10(14):1-17. doi: 10.1186/1471-2210-10-14
27. Liu Y, Ramirez J, Mj R (2012) Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. Br J Clin Pharmacol 71:917-920. doi: 10.1111/j.1365-2125.2011.03911.x
28. Masubuchi Y, Ose A, Horie T (2002) Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine. Drug Metab Dispos 30:1143-1148. doi: 10.1124/dmd.30.10.1143
29. Medioni J, Cojocarasu O, Banu E, Queudeville AC, Halimi P, Oudard S (2007) Reversible encephalopathy syndrome secondary to sunitinib for metastatic cell carcinoma patient. Targeted Oncol 2:193-195. doi: 10.1007/s11523-007-0050-9
30. Mitchell JA, Warner TD (1999) Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 128:1121-1132. doi: 10.1038/sj.bjp.0702897
31. Nassar I, Pasupati T, Judson JP, Segarra I (2009) Reduced exposure of imatinib after coadministration with acetaminophen to mice. Indian J Pharmacol 41:167-172. doi: 10.4103/0253-7613.56071
32. Nassar I, Pasupati T, Judson JP, Segarra I (2010) Histopathological study of the hepatic and renal toxicity associated to the coadministration of imatinib and acetaminophen in a preclinical mouse model. Mal J Path 32:1-11
33. Ng LE, Halliwell B, Wong KP (2008) Nephrotoxic cell death by diclofenac and meloxicam. Biochem Biophys Res Commun 369:873-877. doi: 10.1016/j.bbrc.2008. 02.116
34. Nicholaou T, Wong R, Davis ID (2007) Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet 369:1923-1924. doi: 10.1016/S0140-6736(07)60903-9
35. Njoku DB (2010) Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury: a review. Expert Opin Drug Metab Toxicol 6:519-531. doi: 10.1517/17425251003601979
36. O'Brien RT, Walker KR, Osgood TL (2004) Sonographic features of drug-induced splenic congestion. Vet Radiol Ultrasound 45:225-227. doi: 10.1111/j.1740-8261.2004.04039.x
37. Petroianu A (2007) Drug-induced splenic enlargement. Expert Opinion Drug Safety 6:199-206. doi: 10.1517/14740338.6.2.199
38. Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mando OG (2007) Imatinib-induced fatal acute liver failure. World J Gastroentero 13:6608-6611
39. Riechelmann RP, Giglio AD (2009) Drug interactions in oncology: how common are they? Ann Oncol 20:1907-1912. doi: 10.1093/annonc/mdp369
40. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK (2007) Potential drug interactions and duplicate prescriptions among cancer patients. J Nat Cancer Institute 99:592-600. doi: 10.1093/jnci/djk130
41. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreice R, Bulkowski RM (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81-83. doi: 10.1093/jnci/djk008
42. Roskoski R (2007) Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Bioph Res Co 356:323-328. doi: 10.1016/j.bbrc.2007.02.156
43. Sarda S, Page C, Pickup K, Schulz-Utermoehl T, Wilson I (2012) Diclofenac metabolism in the mouse: novel in vivo metabolites identified by high performance liquid chromatography coupled to linear ion trap mass spectrometry. Xenobiotica 42:179-194. doi: 10.3109/00498254.2011.607865
44. Shimeda Y, Hirotani Y, Akimoyo Y, Shindou K, Ijiri Y, Nishihori T, Tanaka K (2005) Protective effects of capsaicin against cicplatin-induced nephrotoxicity in rats. Biol Pharm Bull 28:1635-1638. doi: 10.1248/bpb.28.1635
45. Singhal SS, Sehrawat A, Sahu M, Singhal P, Vatsyayan R, Lelsani PCR, Yadav S, Awasthi S (2009) RLIP76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer 126:1327-1338. doi: 10.1002/ijc.24767
46. Soo GW, Law JHK, Kan E, Tan SY, Lim WY, Chay G, Bukhari NI, Segarra I (2010) Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice. Anti-Cancer Drugs 21:695-703. doi: 10.1097/CAD.0b013e32833c93b3
47. Stirnimann G, Kessebohm K, Lauterburg B (2010) Liver injury caused by drugs: an update. Swiss Med Wkly 140:w13080. doi: 10.4414/smw.2010.13080
48. Struthmann L, Hellwig N, Pircher J, Sohn HY, Buerkle MA, Klauss V, Mannell H, Pohl U, Krotz F (2009) Prothrombotic effects of diclofenac on arteriolar platelet activation and thrombosis in vivo. J Thromb Haemost 10:1727-1735. doi: 10.1111/j.1538-7836.2009.03582.x
49. Tan SY, Lim WY, Soo GW, Law JHK, Kan E, Chay G, Bukhari NI, Segarra I (2011) Metronidazole leads to enhanced uptake of imatinib in brain, liver and kidney without affecting its plasma pharmacokinetics in mice. J Pharm Pharmacol 63:918-925. doi: 10.1111/j.2042-7158.2011.01296.x
50. Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH (2012a) Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG1) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer 130:223-233. doi: 10.1002/ijc.26000
51. Tang SC, Lankheet NA, Poller B, Wagenaar E, Beijnen JH, Schinkel AH (2012b) P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restric brain accumulation of the active sunitinib metabolite N-desethyl sunitinib. J Pharmacol Exp Ther 341:164-173. doi: 10.1124/jpet.111.186908
52. Usui T, Mise M, Hashizume T, Yabuki M, Komuro S (2009) Evaluation potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab Dispos 37:2386-92. doi: 10.1124/dmd.109.028860
53. van Erp NP, Gelderblom H, Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35:692-706. doi: 10.1016/j.ctrv.2009.08.004
54. van Leeuven JS, Unlü B, Vermeulen NP, Vos JC (2011a) Differential involvement of mitochondrial dysfunction, cytochrome P450 activity, and active transport in the toxicity of structurally related NSAIDs. Toxicol In Vitro 26:197-205. doi: 10.1016/j.tiv.2011.11.013
55. van Leeuwen JS, Orij R, Luttik MA, Smits GJ, Vermeulen NP, Vos JC (2011b) Subunits Rip1p and Cox9p of the respiratory chain contribute to diclofenac-induced mitochondrial dysfunction. Microbiol 157:685-694. doi: 10.1099/mic.0.044578-0
56. Vane J (2003) The mechanism of action of anti-inflammatory drugs. Int J Clin Pract 135:2
57. Waldon DJ, Teffera Y, Colletti AE, Liu J, Zurcher D, Copeland KW, Zhao Z (2010) Identification of quinone imine containing glutathione conjugates of diclofenac in rat bile. Chem Res Toxicol 23:1947-1953. doi: 10.1021/tx100296v
58. Weise AM, Liu CY, Shields AF (2009) Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine. Ann Pharmacother 43:761-766. doi: 10.1345/aph.1L528
59. Weiss SC, Emanuel LL, Fairclough DL, Emanuel EJ (2001) Understanding the experience of pain in terminally ill patients. Lancet 357:1311-1315. doi: 10.1016/S0140-6736(00)04515-3
60. Yamaki K, Yoshino S (2012) Tyrosine kinase inhibitor sunitinib relieves systemic and oral antigen-induced anaphylaxes in mice. Allergy 67:114-122. doi: 10.1111/j.1398-9995.2011.02717.x
61. Yu LJ, Chen Y, Deninno MP, O'Connell TN, Hop CE (2005) Identification of a novel glutathione adduct of diclofenac, 4′-hydroxy-2′-glutathio- descholoro-diclofenac, upon incubation with human liver microsomes. Drug Metab Dispos 33:484-488. doi: 10.1124/dmd.104.002840
62. Zhou Q, Gallo JM (2009) Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. Neuro-Oncology 11:301-310. doi: 10.1215/15228517-2008-088